APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Anti-Obesity Drugs (Anti-obesity Medication)

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Anti-Obesity Drugs (Anti-obesity Medication) Industry Growth and Trends Forecast to 2032

20 December 2025126 pages

Choose your research edition.

Industry ResearchAnti-Obesity Drugs (Anti-obesity Medication) Industry Research Report 2026150 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-Obesity Drugs (Anti-obesity Medication) Industry Growth and Trends Forecast to 2032126 pages · $3,450 USDMarket StructureGlobal Anti-Obesity Drugs (Anti-obesity Medication) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-Obesity Drugs (Anti-obesity Medication) Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-Obesity Drugs (Anti-obesity Medication) Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Anti-Obesity Drugs (Anti-obesity Medication) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Anti-Obesity Drugs (Anti-obesity Medication) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Anti-Obesity Drugs (Anti-obesity Medication) is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anti-Obesity Drugs (Anti-obesity Medication) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Anti-Obesity Drugs (Anti-obesity Medication) include Eisai, Sanofi, Novo Nordisk, Merck, F.Hoffmann-La Roche, Pfizer, GlaxoSmithKline, Bayer AG and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Anti-Obesity Drugs (Anti-obesity Medication) market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Anti-Obesity Drugs (Anti-obesity Medication) market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Anti-Obesity Drugs (Anti-obesity Medication) market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Anti-Obesity Drugs (Anti-obesity Medication).

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Anti-Obesity Drugs (Anti-obesity Medication) market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Anti-Obesity Drugs (Anti-obesity Medication) Market by Company

Eisai

Sanofi

Novo Nordisk

Merck

F.Hoffmann-La Roche

Pfizer

GlaxoSmithKline

Bayer AG

AstraZeneca

Zafgan

Vivus

Shionogi

Rhythm Pharmaceuticals

Orexigen Therapeutics

Norgine

Boehringer Ingelheim

Arena Pharmaceuticals

Amylin

Alizyme

Alizyme

Anti-Obesity Drugs (Anti-obesity Medication) Segment by Type

Rx Drug

OTC Drug

Anti-Obesity Drugs (Anti-obesity Medication) Segment by Application

Middle Aged (41-60)

Juvenile (7-17)

Youth (18-40)

Elderly (Above 60)

Childhood (0-6)

Anti-Obesity Drugs (Anti-obesity Medication) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Obesity Drugs (Anti-obesity Medication) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-Obesity Drugs (Anti-obesity Medication) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Obesity Drugs (Anti-obesity Medication).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Anti-Obesity Drugs (Anti-obesity Medication) manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Anti-Obesity Drugs (Anti-obesity Medication) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Rx Drug Table 2. Major Company of OTC Drug Table 3. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021-2026) & (k units) Table 5. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Volume by Type (2021-2026) Table 6. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021-2026) & (US$ Million) Table 7. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Value by Type (2021-2026) Table 8. Global Anti-Obesity Drugs (Anti-obesity Medication) Price by Type (2021-2026) & (US$/unit) Table 9. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2027-2032) & (k units) Table 10. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Volume by Type (2027-2032) Table 11. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2027-2032) & (US$ Million) Table 12. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Value by Type (2027-2032) Table 13. Global Anti-Obesity Drugs (Anti-obesity Medication) Price by Type (2027-2032) & (US$/unit) Table 14. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021-2026) & (k units) Table 15. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021-2026) & (k units) Table 17. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021-2026) & (k units) Table 19. Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021-2026) & (k units) Table 21. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021-2026) & (k units) Table 23. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021-2026) & (US$ Million) Table 24. Anti-Obesity Drugs (Anti-obesity Medication) Industry Trends Table 25. Anti-Obesity Drugs (Anti-obesity Medication) Industry Drivers Table 26. Anti-Obesity Drugs (Anti-obesity Medication) Industry Opportunities and Challenges Table 27. Anti-Obesity Drugs (Anti-obesity Medication) Industry Restraints Table 28. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Company (2021-2026) Table 30. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Company (2021-2026) & (k units) Table 31. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Share by Company (2021-2026) Table 32. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Price by Company (2021-2026) & (US$/unit) Table 33. Global Anti-Obesity Drugs (Anti-obesity Medication) Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Anti-Obesity Drugs (Anti-obesity Medication) Major Company Production Sites and Headquarters Table 35. Global Anti-Obesity Drugs (Anti-obesity Medication) Company, Product Type & Application Table 36. Global Anti-Obesity Drugs (Anti-obesity Medication) Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Anti-Obesity Drugs (Anti-obesity Medication) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region (2021-2026) & (k units) Table 41. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Volume by Region (2021-2026) Table 42. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region (2021-2026) & (US$ Million) Table 43. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Value by Region (2021-2026) Table 44. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 45. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region (2027-2032) & (k units) Table 46. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Volume by Region (2027-2032) Table 47. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region (2027-2032) & (US$ Million) Table 48. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Value by Region (2027-2032) Table 49. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 50. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021-2026) & (k units) Table 52. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Volume by Application (2021-2026) Table 53. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021-2026) & (US$ Million) Table 54. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Value by Application (2021-2026) Table 55. Global Anti-Obesity Drugs (Anti-obesity Medication) Price by Application (2021-2026) & (US$/unit) Table 56. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2027-2032) & (k units) Table 57. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Volume by Application (2027-2032) Table 58. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2027-2032) & (US$ Million) Table 59. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Value by Application (2027-2032) Table 60. Global Anti-Obesity Drugs (Anti-obesity Medication) Price by Application (2027-2032) & (US$/unit) Table 61. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021-2026) & (k units) Table 62. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021-2026) & (k units) Table 64. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021-2026) & (k units) Table 66. Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021-2026) & (k units) Table 68. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021-2026) & (k units) Table 70. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021-2026) & (US$ Million) Table 71. Eisai Company Information Table 72. Eisai Business Overview Table 73. Eisai Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. Eisai Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 75. Eisai Recent Development Table 76. Sanofi Company Information Table 77. Sanofi Business Overview Table 78. Sanofi Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Sanofi Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 80. Sanofi Recent Development Table 81. Novo Nordisk Company Information Table 82. Novo Nordisk Business Overview Table 83. Novo Nordisk Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. Novo Nordisk Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 85. Novo Nordisk Recent Development Table 86. Merck Company Information Table 87. Merck Business Overview Table 88. Merck Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Merck Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 90. Merck Recent Development Table 91. F.Hoffmann-La Roche Company Information Table 92. F.Hoffmann-La Roche Business Overview Table 93. F.Hoffmann-La Roche Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. F.Hoffmann-La Roche Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 95. F.Hoffmann-La Roche Recent Development Table 96. Pfizer Company Information Table 97. Pfizer Business Overview Table 98. Pfizer Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. Pfizer Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 100. Pfizer Recent Development Table 101. GlaxoSmithKline Company Information Table 102. GlaxoSmithKline Business Overview Table 103. GlaxoSmithKline Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. GlaxoSmithKline Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 105. GlaxoSmithKline Recent Development Table 106. Bayer AG Company Information Table 107. Bayer AG Business Overview Table 108. Bayer AG Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. Bayer AG Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 110. Bayer AG Recent Development Table 111. AstraZeneca Company Information Table 112. AstraZeneca Business Overview Table 113. AstraZeneca Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 114. AstraZeneca Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 115. AstraZeneca Recent Development Table 116. Zafgan Company Information Table 117. Zafgan Business Overview Table 118. Zafgan Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 119. Zafgan Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 120. Zafgan Recent Development Table 121. Vivus Company Information Table 122. Vivus Business Overview Table 123. Vivus Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 124. Vivus Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 125. Vivus Recent Development Table 126. Shionogi Company Information Table 127. Shionogi Business Overview Table 128. Shionogi Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 129. Shionogi Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 130. Shionogi Recent Development Table 131. Rhythm Pharmaceuticals Company Information Table 132. Rhythm Pharmaceuticals Business Overview Table 133. Rhythm Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 134. Rhythm Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 135. Rhythm Pharmaceuticals Recent Development Table 136. Orexigen Therapeutics Company Information Table 137. Orexigen Therapeutics Business Overview Table 138. Orexigen Therapeutics Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 139. Orexigen Therapeutics Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 140. Orexigen Therapeutics Recent Development Table 141. Norgine Company Information Table 142. Norgine Business Overview Table 143. Norgine Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 144. Norgine Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 145. Norgine Recent Development Table 146. Boehringer Ingelheim Company Information Table 147. Boehringer Ingelheim Business Overview Table 148. Boehringer Ingelheim Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 149. Boehringer Ingelheim Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 150. Boehringer Ingelheim Recent Development Table 151. Arena Pharmaceuticals Company Information Table 152. Arena Pharmaceuticals Business Overview Table 153. Arena Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 154. Arena Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 155. Arena Pharmaceuticals Recent Development Table 156. Amylin Company Information Table 157. Amylin Business Overview Table 158. Amylin Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 159. Amylin Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 160. Amylin Recent Development Table 161. Alizyme Company Information Table 162. Alizyme Business Overview Table 163. Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 164. Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 165. Alizyme Recent Development Table 166. Alizyme Company Information Table 167. Alizyme Business Overview Table 168. Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 169. Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 170. Alizyme Recent Development Table 171. North America Anti-Obesity Drugs (Anti-obesity Medication) Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 172. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2026) & (k units) Table 173. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Country (2021-2026) Table 174. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Forecast by Country (2027-2032) & (k units) Table 175. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share Forecast by Country (2027-2032) Table 176. North America Anti-Obesity Drugs (Anti-obesity Medication) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 177. North America Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country (2021-2026) & (US$ Million) Table 178. North America Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Country (2021-2026) Table 179. North America Anti-Obesity Drugs (Anti-obesity Medication) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 180. North America Anti-Obesity Drugs (Anti-obesity Medication) Market Share Forecast by Country (2027-2032) Table 181. Europe Anti-Obesity Drugs (Anti-obesity Medication) Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 182. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2026) & (k units) Table 183. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Country (2021-2026) Table 184. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Forecast by Country (2027-2032) & (k units) Table 185. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share Forecast by Country (2027-2032) Table 186. Europe Anti-Obesity Drugs (Anti-obesity Medication) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 187. Europe Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country (2021-2026) & (US$ Million) Table 188. Europe Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Country (2021-2026) Table 189. Europe Anti-Obesity Drugs (Anti-obesity Medication) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 190. Europe Anti-Obesity Drugs (Anti-obesity Medication) Market Share Forecast by Country (2027-2032) Table 191. Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 192. Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2026) & (k units) Table 193. Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Country (2021-2026) Table 194. Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales Forecast by Country (2027-2032) & (k units) Table 195. Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share Forecast by Country (2027-2032) Table 196. Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 197. Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country (2021-2026) & (US$ Million) Table 198. Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Country (2021-2026) Table 199. Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 200. Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Market Share Forecast by Country (2027-2032) Table 201. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 202. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2026) & (k units) Table 203. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Country (2021-2026) Table 204. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales Forecast by Country (2027-2032) & (k units) Table 205. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share Forecast by Country (2027-2032) Table 206. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 207. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country (2021-2026) & (US$ Million) Table 208. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Country (2021-2026) Table 209. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 210. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Market Share Forecast by Country (2027-2032) Table 211. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 212. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2026) & (k units) Table 213. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Country (2021-2026) Table 214. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales Forecast by Country (2027-2032) & (k units) Table 215. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share Forecast by Country (2027-2032) Table 216. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 217. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country (2021-2026) & (US$ Million) Table 218. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Country (2021-2026) Table 219. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 220. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Market Share Forecast by Country (2027-2032) Table 221. Key Raw Materials Table 222. Raw Materials Key Suppliers Table 223. Anti-Obesity Drugs (Anti-obesity Medication) Distributors List Table 224. Anti-Obesity Drugs (Anti-obesity Medication) Customers List Table 225. Research Programs/Design for This Report Table 226. Authors List of This Report Table 227. Secondary Sources Table 228. Primary Sources List of Figures Figure 1. Anti-Obesity Drugs (Anti-obesity Medication) Image Figure 2. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size (2021-2032) & (US$ Million) Figure 4. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales (2021-2032) & (k units) Figure 5. Rx Drug Image Figure 6. Global Rx Drug Sales YoY Growth (2021-2032) & (k units) Figure 7. OTC Drug Image Figure 8. Global OTC Drug Sales YoY Growth (2021-2032) & (k units) Figure 9. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Type 2025 VS 2032 Figure 11. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Volume by Type in 2025 Figure 12. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Value by Type in 2025 Figure 13. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Volume by Type in 2025 Figure 14. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Value by Type in 2025 Figure 17. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Anti-Obesity Drugs (Anti-obesity Medication) Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Middle Aged (41-60) Image Figure 24. Global Middle Aged (41-60) Sales YoY Growth (2021-2032) & (k units) Figure 25. Juvenile (7-17) Image Figure 26. Global Juvenile (7-17) Sales YoY Growth (2021-2032) & (k units) Figure 27. Youth (18-40) Image Figure 28. Global Youth (18-40) Sales YoY Growth (2021-2032) & (k units) Figure 29. Elderly (Above 60) Image Figure 30. Global Elderly (Above 60) Sales YoY Growth (2021-2032) & (k units) Figure 31. Childhood (0-6) Image Figure 32. Global Childhood (0-6) Sales YoY Growth (2021-2032) & (k units) Figure 33. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Application 2025 VS 2032 Figure 35. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Volume by Application in 2025 Figure 36. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Value by Application in 2025 Figure 37. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Volume by Application in 2025 Figure 38. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Value by Application in 2025 Figure 41. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share in Value by Application in 2025 Figure 45. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 46. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 50. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 62. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Anti-Obesity Drugs (Anti-obesity Medication) Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Anti-Obesity Drugs (Anti-obesity Medication) Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Rx Drug
  • OTC Drug
Applications
  • Middle Aged (41-60)
  • Juvenile (7-17)
  • Youth (18-40)
  • Elderly (Above 60)
  • Childhood (0-6)
Companies covered
  • Eisai
  • Sanofi
  • Novo Nordisk
  • Merck
  • F.Hoffmann-La Roche
  • Pfizer
  • GlaxoSmithKline
  • Bayer AG
  • AstraZeneca
  • Zafgan
  • Vivus
  • Shionogi
  • Rhythm Pharmaceuticals
  • Orexigen Therapeutics
  • Norgine
  • Boehringer Ingelheim
  • Arena Pharmaceuticals
  • Amylin
  • Alizyme
  • Alizyme

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Anti-Obesity Drugs (Anti-obesity Medication) Market by Type
  6. 1.3.1 Rx Drug
  7. 1.3.2 OTC Drug
  8. 1.4 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Type
  9. 1.4.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Anti-Obesity Drugs (Anti-obesity Medication) Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Anti-Obesity Drugs (Anti-obesity Medication) Industry Trends
  2. 2.2 Anti-Obesity Drugs (Anti-obesity Medication) Industry Drivers
  3. 2.3 Anti-Obesity Drugs (Anti-obesity Medication) Industry Opportunities and Challenges
  4. 2.4 Anti-Obesity Drugs (Anti-obesity Medication) Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2026)
  2. 3.2 Global Top Players by Anti-Obesity Drugs (Anti-obesity Medication) Sales (2021-2026)
  3. 3.3 Global Top Players by Anti-Obesity Drugs (Anti-obesity Medication) Price (2021-2026)
  4. 3.4 Global Anti-Obesity Drugs (Anti-obesity Medication) Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Anti-Obesity Drugs (Anti-obesity Medication) Major Company Production Sites & Headquarters
  6. 3.6 Global Anti-Obesity Drugs (Anti-obesity Medication) Company, Product Type & Application
  7. 3.7 Global Anti-Obesity Drugs (Anti-obesity Medication) Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Anti-Obesity Drugs (Anti-obesity Medication) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Anti-Obesity Drugs (Anti-obesity Medication) Tier 1, Tier 2, and Tier 3
4 Anti-Obesity Drugs (Anti-obesity Medication) Regional Status and Outlook
  1. 4.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Historic Market Size by Region
  3. 4.2.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Forecasted Market Size by Region
  7. 4.3.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Anti-Obesity Drugs (Anti-obesity Medication) by Application
  1. 5.1 Anti-Obesity Drugs (Anti-obesity Medication) Market by Application
  2. 5.1.1 Middle Aged (41-60)
  3. 5.1.2 Juvenile (7-17)
  4. 5.1.3 Youth (18-40)
  5. 5.1.4 Elderly (Above 60)
  6. 5.1.5 Childhood (0-6)
  7. 5.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Application
  8. 5.2.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size Overview by Application (2021-2032)
  9. 5.2.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Historic Market Size Review by Application (2021-2026)
  10. 5.2.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Forecasted Market Size by Application (2027-2032)
  11. 5.3 Key Regions Market Size by Application
  12. 5.3.1 North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Breakdown by Application (2021-2026)
  13. 5.3.2 Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Breakdown by Application (2021-2026)
  14. 5.3.3 Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales Breakdown by Application (2021-2026)
  15. 5.3.4 South America Anti-Obesity Drugs (Anti-obesity Medication) Sales Breakdown by Application (2021-2026)
  16. 5.3.5 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Eisai
  2. 6.1.1 Eisai Company Information
  3. 6.1.2 Eisai Business Overview
  4. 6.1.3 Eisai Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Eisai Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  6. 6.1.5 Eisai Recent Developments
  7. 6.2 Sanofi
  8. 6.2.1 Sanofi Company Information
  9. 6.2.2 Sanofi Business Overview
  10. 6.2.3 Sanofi Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Sanofi Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  12. 6.2.5 Sanofi Recent Developments
  13. 6.3 Novo Nordisk
  14. 6.3.1 Novo Nordisk Company Information
  15. 6.3.2 Novo Nordisk Business Overview
  16. 6.3.3 Novo Nordisk Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Novo Nordisk Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  18. 6.3.5 Novo Nordisk Recent Developments
  19. 6.4 Merck
  20. 6.4.1 Merck Company Information
  21. 6.4.2 Merck Business Overview
  22. 6.4.3 Merck Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Merck Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  24. 6.4.5 Merck Recent Developments
  25. 6.5 F.Hoffmann-La Roche
  26. 6.5.1 F.Hoffmann-La Roche Company Information
  27. 6.5.2 F.Hoffmann-La Roche Business Overview
  28. 6.5.3 F.Hoffmann-La Roche Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 F.Hoffmann-La Roche Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  30. 6.5.5 F.Hoffmann-La Roche Recent Developments
  31. 6.6 Pfizer
  32. 6.6.1 Pfizer Company Information
  33. 6.6.2 Pfizer Business Overview
  34. 6.6.3 Pfizer Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Pfizer Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  36. 6.6.5 Pfizer Recent Developments
  37. 6.7 GlaxoSmithKline
  38. 6.7.1 GlaxoSmithKline Company Information
  39. 6.7.2 GlaxoSmithKline Business Overview
  40. 6.7.3 GlaxoSmithKline Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 GlaxoSmithKline Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  42. 6.7.5 GlaxoSmithKline Recent Developments
  43. 6.8 Bayer AG
  44. 6.8.1 Bayer AG Company Information
  45. 6.8.2 Bayer AG Business Overview
  46. 6.8.3 Bayer AG Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Bayer AG Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  48. 6.8.5 Bayer AG Recent Developments
  49. 6.9 AstraZeneca
  50. 6.9.1 AstraZeneca Company Information
  51. 6.9.2 AstraZeneca Business Overview
  52. 6.9.3 AstraZeneca Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 AstraZeneca Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  54. 6.9.5 AstraZeneca Recent Developments
  55. 6.10 Zafgan
  56. 6.10.1 Zafgan Company Information
  57. 6.10.2 Zafgan Business Overview
  58. 6.10.3 Zafgan Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Zafgan Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  60. 6.10.5 Zafgan Recent Developments
  61. 6.11 Vivus
  62. 6.11.1 Vivus Company Information
  63. 6.11.2 Vivus Business Overview
  64. 6.11.3 Vivus Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Vivus Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  66. 6.11.5 Vivus Recent Developments
  67. 6.12 Shionogi
  68. 6.12.1 Shionogi Company Information
  69. 6.12.2 Shionogi Business Overview
  70. 6.12.3 Shionogi Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Shionogi Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  72. 6.12.5 Shionogi Recent Developments
  73. 6.13 Rhythm Pharmaceuticals
  74. 6.13.1 Rhythm Pharmaceuticals Company Information
  75. 6.13.2 Rhythm Pharmaceuticals Business Overview
  76. 6.13.3 Rhythm Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Rhythm Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  78. 6.13.5 Rhythm Pharmaceuticals Recent Developments
  79. 6.14 Orexigen Therapeutics
  80. 6.14.1 Orexigen Therapeutics Company Information
  81. 6.14.2 Orexigen Therapeutics Business Overview
  82. 6.14.3 Orexigen Therapeutics Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Orexigen Therapeutics Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  84. 6.14.5 Orexigen Therapeutics Recent Developments
  85. 6.15 Norgine
  86. 6.15.1 Norgine Company Information
  87. 6.15.2 Norgine Business Overview
  88. 6.15.3 Norgine Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Norgine Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  90. 6.15.5 Norgine Recent Developments
  91. 6.16 Boehringer Ingelheim
  92. 6.16.1 Boehringer Ingelheim Company Information
  93. 6.16.2 Boehringer Ingelheim Business Overview
  94. 6.16.3 Boehringer Ingelheim Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Boehringer Ingelheim Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  96. 6.16.5 Boehringer Ingelheim Recent Developments
  97. 6.17 Arena Pharmaceuticals
  98. 6.17.1 Arena Pharmaceuticals Company Information
  99. 6.17.2 Arena Pharmaceuticals Business Overview
  100. 6.17.3 Arena Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Arena Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  102. 6.17.5 Arena Pharmaceuticals Recent Developments
  103. 6.18 Amylin
  104. 6.18.1 Amylin Company Information
  105. 6.18.2 Amylin Business Overview
  106. 6.18.3 Amylin Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Amylin Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  108. 6.18.5 Amylin Recent Developments
  109. 6.19 Alizyme
  110. 6.19.1 Alizyme Company Information
  111. 6.19.2 Alizyme Business Overview
  112. 6.19.3 Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  114. 6.19.5 Alizyme Recent Developments
  115. 6.20 Alizyme
  116. 6.20.1 Alizyme Company Information
  117. 6.20.2 Alizyme Business Overview
  118. 6.20.3 Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  120. 6.20.5 Alizyme Recent Developments
7 North America by Country
  1. 7.1 North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country
  2. 7.1.1 North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2026)
  4. 7.1.3 North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Forecast by Country (2027-2032)
  5. 7.2 North America Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country
  6. 7.2.1 North America Anti-Obesity Drugs (Anti-obesity Medication) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country (2021-2026)
  8. 7.2.3 North America Anti-Obesity Drugs (Anti-obesity Medication) Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country
  2. 8.1.1 Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2026)
  4. 8.1.3 Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country
  6. 8.2.1 Europe Anti-Obesity Drugs (Anti-obesity Medication) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country (2021-2026)
  8. 8.2.3 Europe Anti-Obesity Drugs (Anti-obesity Medication) Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country
  2. 9.1.1 Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country
  6. 9.2.1 Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country
  2. 10.1.1 South America Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2026)
  4. 10.1.3 South America Anti-Obesity Drugs (Anti-obesity Medication) Sales Forecast by Country (2027-2032)
  5. 10.2 South America Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country
  6. 10.2.1 South America Anti-Obesity Drugs (Anti-obesity Medication) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country (2021-2026)
  8. 10.2.3 South America Anti-Obesity Drugs (Anti-obesity Medication) Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country
  2. 11.1.1 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country
  6. 11.2.1 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Anti-Obesity Drugs (Anti-obesity Medication) Value Chain Analysis
  2. 12.1.1 Anti-Obesity Drugs (Anti-obesity Medication) Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Anti-Obesity Drugs (Anti-obesity Medication) Production Mode & Process
  7. 12.2 Anti-Obesity Drugs (Anti-obesity Medication) Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Anti-Obesity Drugs (Anti-obesity Medication) Distributors
  10. 12.2.3 Anti-Obesity Drugs (Anti-obesity Medication) Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst